Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mitochondrial peptide deformylase (PDF) is a nuclear-encoded metalloenzyme essential for the maturation of proteins synthesized within the mitochondria (UniProt Q9HBH1; NCBI Gene ID: 64146). In human mitochondria, as in bacteria, protein translation initiates with N-formylmethionine; PDF catalyzes the removal of this N-formyl group from nascent polypeptides, a step that is a prerequisite for subsequent N-terminal methionine excision (PMID: 15103325). This process is vital for the stability and assembly of the 13 proteins encoded by mitochondrial DNA, all of which are core subunits of the oxidative phosphorylation (OXPHOS) machinery (PMID: 20837555). Because many cancer cells rely heavily on mitochondrial biogenesis and OXPHOS to sustain rapid growth, PDF is often overexpressed in various malignancies, making it a promising target for anti-cancer therapy (PMID: 36812345). Inhibitors like the natural product actinonin can trigger mitochondrial proteotoxic stress and apoptosis in cancer cells by blocking this maturation process (PMID: 20837555). However, the high structural similarity between human mitochondrial PDF and bacterial PDF presents a therapeutic challenge, as antibacterial drugs targeting this enzyme must be carefully designed to avoid off-target mitochondrial toxicity in human patients (PMID: 22432445).
Inhibition of the removal of the N-formyl group from the N-terminal methionine of nascent mitochondrial proteins, leading to impaired protein maturation, proteotoxic stress, and mitochondrial dysfunction.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mitochondrial peptide deformylase (PDF).